H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs Joslin Diabetes Center

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
Joslin Diabetes Center
MARank #FEIN 04-2203836

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPJoslin Diabetes Center
Total filings80,813118
Certified %98.23%66.95%
Denied %1.09%0.85%
Withdrawn %0.61%4.24%
Cert-withdrawn %0.07%27.97%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePAMA

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — Joslin Diabetes Center

DOL case-status mix.

Outcome breakdown: Certified 66.9%, Cert-withdrawn 28.0%, Withdrawn 4.2%, Denied 0.8%
Outcome breakdown
OutcomeShare
Certified66.9%
Cert-withdrawn28.0%
Withdrawn4.2%
Denied0.8%
Certified66.9%
Cert-withdrawn28.0%
Withdrawn4.2%
Denied0.8%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
Joslin Diabetes Center
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201012
FY201112
FY201214
FY20138
FY201412
FY20157
FY20167
FY20178
FY20187
FY201910
FY20200
FY20210
FY20220
FY20230
FY20245
FY202511
FY20265

Top 5 occupations — Deloitte Consulting LLP

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.